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Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under
development by Novartis for the potential treatment of
osteoarthritis, rheumatoid arthritis and pain. By late December
2000, phase III trials had been initiated and were ongoing in
December 2001.
Introduction
Following the discovery of the inducible isoform of
cyclooxygenase (COX)-2, the expectation emerged that the
development of new agents that selectively inhibit COX-2
would optimize the analgesic and anti-inflammatory
properties of non-steroidal anti-inflammatory drugs
(NSAIDs), while minimizing the potential for
gastrointestinal (GI) adverse events (mediated by inhibition
of COX-1). It is now appreciated that COX-2 is also
expressed in a variety of non-inflammatory tissues,
including kidney, brain, neoplasms, bone and cartilage,
particularly under 'physiological stress' conditions. In the
kidney, COX-2-derived prostaglandins help modulate
vascular tone in addition to salt and water homeostasis. It
is, therefore, not surprising that clinical studies indicate
that selective COX-2 inhibitors, like conventional NSAIDs,
cause comparable rates of edema and hypertension and
may impair renal function in the setting of congestive heart
failure or volume depletion [468857].
To date, only two selective COX-2 inhibitors have been
successfully launched. Celecoxib (celebrex) is approved for
the treatment of osteoarthritis (OA) and rheumatoid
arthritis (RA), and for the management of pain indications,
such as pain associated with cancer and dysmenorrhea.
The approved indications for rofecoxib (Vioxx) are
treatment of OA, acute pain and dysmenorrhea. Usage of
these COX-2 inhibitors increased rapidly until a study was
published in the August 2001 issue of Journal of the America
Medical Association. The authors re-analyzed data from
pivotal clinical trials and found that both rofecoxib and
celecoxib might have cardiac side effects [451465].
Subsequent meta-analyses failed to confirm this finding,
however, and the adverse cardiac effect has been limited to
one rofecoxib trial (VIoxx Gastrointestinal Outcomes
Research; VIGOR) in RA [451465].
Lumiracoxib is a second-generation COX-2 inhibitor
developed by Novartis for the potential treatment of OA, RA
and pain [342937]. It is currently in the phase III TARGET
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Trial) trial, which will examine, as a primary objective, the
GI safety of lumiracoxib compared with NSAIDs, in
addition to cardiovascular safety as a specified secondary
endpoint [451913].
Synthesis and SAR
The synthesis of lumiracoxib involves the coupling of N,N-
dimethyl-5-methyl-2-iodophenylacetamide with 2-chloro-
6-fluoroaniline in the presence of copper powder, copper(I)
iodide and anhydrous potassium carbonate, and refluxing
the mixture in xylenes for 48 h. Work-up led to the
isolation of lumiracoxib, which was characterized by
melting point (158 to 159oC) [WO-09911605].
Four claimed routes for the process preparation of
lumiracoxib are reported in WO-00123346. For example, 4-
bromotoluene and 2-chloro-6-fluoroaniline are coupled in
the presence of palladium catalyst under Buchwald
chemistry conditions. The resulting diphenylamine
undergoes N-acylation with chloroacetyl chloride before
cyclization to the corresponding lactam under Friedel-
Crafts alkylation conditions. Lumiracoxib is finally
liberated by hydrolysis.
A formulation, comprising lumiracoxib (200 mg),
microcrystalline cellulose (103.4 mg), lactose (46.6 mg),
povidone (16 mg), titanium dioxide (16 mg), croscarmellose
sodium (16 mg) and magnesium stearate (2 mg), is
specifically claimed in WO-00220090.
Pharmacology
Studies performed in vitro revealed that the COX-2
selectivity of lumiracoxib was 100- and 1400-fold higher
than that of the COX inhibitors diclofenac and naproxen,
respectively. In primary human fibroblasts induced with
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IL-1 to synthesize COX-2 and HEK293 cells stably
transfected to constitutively express COX-1, the
lumiracoxib prodrug, 5-alkyl-2-arylaminophenylacetic
acid, had an IC50 value of 0.007 µM against COX-2 with no
activity against COX-1 at 30 µM. This compound showed
an ED50 value in the range of 0.2 to 0.6 mg/kg po in the rat
air pouch model for measuring inhibition of PGE2
formation [WO-09911605].
The in vivo inhibition of thromboxane B2 was investigated
in serum from fasted rats that had been administered
lumiracoxib (800 mg) or placebo 30 min prior to sacrifice.
No significant inhibition was observed compared to
placebo, and the ED50 value was 50- to 100-fold greater than
for COX-2 inhibition [411639], [WO-09911605].
In the Randall-Selitto paw pressure assay of anti-
nociception in Wistar rats, lumiracoxib increased the pain
threshold in an inflamed paw at 10 mg/kg po. This was
selective with no threshold elevation in the non-inflamed
paw [WO-09911605].
Metabolism
Lumiracoxib shows no accumulation in plasma, does not
interact with antacids and has no effect on platelet
aggregation at 2- to 4-fold the therapeutic dose [468743]. It
has a unique pharmacokinetic profile; it is an acid, and has
a high protein-binding capacity (99.9%) and a t1/2 of 3 to 6 h,
but can still be applied once-daily [468743], [WO-00220090].
OA patients were administered doses of 50, 100 and 200
mg tid or 400 mg/day, and the changes in AUC and Cmax
were measured on day 28. This produced Tmax values of 2 to
3 h, with Cmax values of 4378 and 4788 ng/ml at the 200 mg
bid and 400 mg/day doses, respectively; AUC values were
dose proportional and were similar on days 0 and 28,
suggesting that lumiracoxib rapidly reaches steady state in
plasma [WO-00220090].
Toxicity
The lumiracoxib prodrug is free of gastric ulcerogenic effects
(at 100 mg/kg po) and has only minimal effects on intestinal
permeability (at 30 mg/kg po) in rats [WO-09911605].
Clinical Development
Phase I
Phase I trials showed that lumiracoxib was well tolerated at
up to 800 mg and that there were no serious adverse effects
or clinically significant laboratory abnormalities [342937].
In one trial, 60 healthy male volunteers received either 200
mg bid of lumiracoxib, 500 mg bid of naproxen or placebo
for 7 days. The presence of gastric or duodenal erosions
was determined by endoscopy before dosing began and
again following 7 days of dosing. Erosions were detected in
13 of 20 subjects in the naproxen group and 1 of 20 in the
placebo group, whereas no erosions were observed in the
lumiracoxib group. In another trial of 25 healthy
volunteers, lumiracoxib (800 mg/day), naproxen (500 mg
bid) or placebo were administered for 8 days. Ulcers or
erosions were detected in 75% of the naproxen group and
12% of the placebo group, although none were detected in
the lumiracoxib group [451313], [451315], [451430] [451715],
[451842].
In vivo studies confirmed the COX-2 selectivity of lumiracoxib;
in healthy volunteers treated for 8 days, it inhibited
lipopolysaccharide (LPS)-induced PGE2 synthesis in whole
blood more effectively than naproxen, with mean PGE2
concentrations of 7054, 20654 and 4729 pg/ml for naproxen
(500 mg bid), placebo and lumiracoxib (800 mg/day),
respectively. It had no significant effect on gastric mucosal
PGE2 expression (mean gastric mucosal PGE2 concentrations =
68, 221 and 156 pg/mg for the naproxen, placebo and
lumiracoxib groups, respectively) and blood platelet
thromboxane B2 concentrations (mean platelet thromboxane
B2 concentrations = 10, 397 and 302 ng/ml for the naproxen,
placebo and lumiracoxib groups, respectively) [451842].
Another trial in healthy volunteers (n = 6) also revealed that
mean serum concentration of thromboxane B2 in the naproxen
group (500 mg bid) was less than 5% of the mean placebo
group value, whereas mean concentration for the lumiracoxib
group (200 mg bid) was similar to placebo after 6 days of
treatment [451842]. These results suggest that lumiracoxib has
minimal effects on the COX-1 isoform.
Phase II
Phase II trials in OA, RA and pain were initiated in
September 1999 [342937]. In a placebo-controlled, 150-
patient phase II study in dental pain, lumiracoxib (400 mg
single dose) demonstrated a potent analgesic effect
[411639]. A double-blind, randomized, parallel-group
study involving subjects with moderate-to-severe pain
following extraction of two or more impacted third molars
(n = 202), found that treatment with lumiracoxib (400 mg
single dose) resulted in rapid and prolonged pain relief and
was equivalent to ibuprofen and superior to placebo in
analgesic onset (38 min versus 42 min and > 12 h,
respectively) and superior in median time to rescue
medication (> 12 h versus 8 h and 2 h, respectively)
[448856]. Clinical results from placebo-controlled phase II
trials in OA (400 mg/day; n = 94 to 99 patients per arm)
and RA (200 mg bid; n = 87 to 99 patients per arm)
demonstrated that lumiracoxib performs better than
placebo for OA and RA and is comparable to diclofenac (75
mg bid) for RA [411639].
A multinational, dose-ranging trial evaluated the efficacy
of lumiracoxib in patients with OA of the hip and knee (n =
583). Patients were treated for 4 weeks with lumiracoxib
(400 mg/day, 50, 100 or 200 mg bid); diclofenac (75 mg
bid); or placebo. The minimum effective dose of
lumiracoxib was 50 mg bid. All regimens of lumiracoxib
were comparable to diclofenac and superior to placebo in
mean improvements in visual analog scale (VAS) pain,
WOMAC index, HAQ index and global assessments
[468864]. The assessment of the responder rate of
lumiracoxib in OA pain showed that lumiracoxib at 400
mg/day is highly effective for the treatment of patients
with OA. The findings suggested that lumiracoxib provides
the same strong efficacy as high doses of diclofenac (75 mg
bid) in treatment response defined as a 20% reduction in
OA pain intensity based on VAS measure [454848].
A multicenter, double-blind study investigated upper GI
safety and tolerability in 1042 OA patients who were
randomized to one of four treatment groups: 200 or 400
mg/day of lumiracoxib (n = 264 and 260, respectively); 800
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mg tid of ibuprofen (n = 258); or 200 mg/day of celecoxib
(n = 260). Patients were evaluated by endoscopy for
cumulative incidence of GI ulcers (diameter > 3 mm) at
baseline, week 4 and week 13. Frequency of adverse events,
including GI serious adverse events, was also recorded. At
both doses, lumiracoxib demonstrated a superior GI safety
and tolerability profile compared with ibuprofen. With
respect to the occurrence of gastroduodenal ulcers,
lumiracoxib was statistically superior to ibuprofen (p <
0.01). The study showed that 15.7% of patients in the
ibuprofen group experienced ulcers compared with 4.3 and
4.0% in the lumiracoxib groups (200 and 400 mg/day,
respectively), which was comparable to the celecoxib group
(3.2%) [454848], [468909], [468911].
Phase III
A multinational, double-blind, randomized, active-
controlled, parallel-group worldwide study (TARGET) has
been initiated. More than 18,000 patients with OA (50 years
and older) are to receive one year of treatment with either
lumiracoxib (400 mg/day), ibuprofen (800 mg tid) or
naproxen (500 mg bid). The primary safety endpoints
include perforation, obstructions and bleeding, while the
secondary endpoints include cardiovascular events,
combined cardiovascular and gastrointestinal events and
safety [427419], [440183], [451842], [451913]. As of July
2002, interim results of the TARGET study were expected
to be available in 2003, with final results anticipated for
mid-2004 [455859], [458765].
Side Effects and Contraindications
There have been no serious adverse events reported from
the limited number of clinical studies on lumiracoxib
[451842]. Of patients treated with lumiracoxib (200 and 400
mg/day), 4.3 and 4.0% experienced GI ulcers following 13
weeks of treatment, which was comparable to the celecoxib
group (3.2%) and lower than the ibuprofen group (15.7%)
[454848]. Of patients in the lurimacoxib groups, 16.7 and
23.1% experienced upper abdominal pain after 13 weeks
treatment (200 and 400 mg/day, respectively) [468909],
[468911]. Lumiracoxib demonstrates liver and renal safety
comparable to the other COX-2 inhibitors [468743].
Patent Commentary
Novel 5-alkyl-2-arylaminophenylacetic acids with selective
inhibitory properties against COX-2 are claimed by Novartis
in WO-09911605, which was published in March 1999 and
will expire in August 2017. In April 2001, Novartis claimed a
process for preparing 2-phenylamino-5-alkylphenyl acetic
acids, which are stated to be selective COX-2 inhibitors,
comprising cleavage of a novel cyclic lactam intermediate
with a base in WO-00123346. Formulations of lumiracoxib,
suitable for once-daily administration, were claimed by
Novartis in March 2002, in WO-00022290, due to expire in
September 2020.
Current Opinion
Clinical studies have demonstrated that lumiracoxib is
effective in the treatment of dental pain, OA and RA, and is
comparable to the conventional NSAIDs diclofenac and
ibuprofen. Lumiracoxib is well tolerated and its GI safety
profile is superior to conventional NSAIDs. So far, no claim
can be made that this drug is more effective, better
tolerated or more useful than currently available COX-2
inhibitors. Novartis is conducting a clinical trial that will
directly compare lumiracoxib to the current market leaders
to investigate GI and cardiovascular side effects, hoping to
demonstrate that its product has a safety advantage. If this
proves to be the case, lumiracoxib may capture a
substantial portion of the considerable market for COX-2
inhibitors. The theoretical rationale for this advantage is,
however, weak at present.
As with other conventional NSAIDs, there are no data
showing the effects of lumiracoxib on underlying joint
health in the treatment of OA and RA [468870]. As COX-2
is found in cartilage, it is necessary to elucidate the role of
all COX-2 inhibitors, including lumiracoxib, on disease
progression of arthritis using biochemical markers of
cartilage damage and/or novel imaging approaches, such
as magnetic resonance imaging.
Commercial Opinion
In July 2000, Vontobel predicted sales of SFr 100 million in
2003, rising to SFr 1 billion in 2004 [378871]. In November
2000, Lehman Brothers estimated launch in 2003, with
worldwide peak sales of US $750 million in 2011 [392075].
In December 2000, and later in February 2001, Merrill
Lynch predicted sales of SFr 100 million in 2003 and SFr
261 million in 2005 [394812], [411704]. In August 2001,
Deutsche Bank estimated sales of SFr 75 million in 2003,
rising to SFr 700 million in 2005 [422674].
Development history
By September 1999, the company had expected to make regulatory submissions in the fourth quarter of 2002 and to launch
lumiracoxib in late 2003 [342937], [458765]; in October 2002, Novartis revealed that US and EU filings were on track for
December 2002 with launches forecast in 2004 [467193]. In Japan, lumiracoxib was listed as beyond phase II trials for OA, RA
and pain in October 2002 [466916]. In November 2001, it was reported that Novartis planned to look for a commercialization
partner for the compound [430088].
Developer Country Status Indication Date Reference
Novartis AG Switzerland Phase III Pain 11-DEC-00 392881
Novartis AG Switzerland Phase III Rheumatoid arthritis 11-DEC-00 392881
Novartis AG Switzerland Phase III Osteoarthritis 11-DEC-00 392881
Novartis AG Japan Clinical Rheumatoid arthritis 14-OCT-02 466916
Novartis AG Japan Clinical Osteoarthritis 14-OCT-02 466916
Novartis AG Japan Clinical Pain 14-OCT-02 466916
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Literature classifications
Key references relating to the drug are classified according to a set of standard headings to provide a quick guide to the
bibliography. These headings are as follows:
Clinical: Reports of clinical phase studies in volunteers providing, where available, data on the following: whether the
experiment is placebo-controlled or double- or single-blind; number of patients; dosage.
Clinical
Effect Studied Model Used Result Reference
Efficacy in inhibition of
COX-2.
LPS-induced PGE2 synthesis in whole blood.
Phase I trial in healthy volunteers (n = 25)
treated with lumiracoxib (800 mg/day) for 8
days.
Lumiracoxib inhibited PGE2 synthesis. 451842
Efficacy in inhibition of
COX-1.
Gastric mucosal PGE2 expression and blood
platelet thromboxane B2 concentrations. Phase
I trial in healthy volunteers (n = 25) treated with
lumiracoxib (800 mg/day) for 8 days.
Lumiracoxib had no effect on PGE2
and thromboxane B2 production.
451842
GI safety and tolerability A multicenter, double-blind phase II study in OA
patients (n = 1042) randomized to one of four
treatment groups: lumiracoxib (200 or 400
mg/day), ibuprofen (800 mg tid) or celecoxib
(200 mg/day).
Both doses of lumiracoxib
demonstrated a superior GI safety and
tolerability profile compared with
ibuprofen.
454848
468911
Symptomatic relief of OA. A dose-ranging phase II trial evaluating the
efficacy of lumiracoxib in patients with OA of the
hip and knee (n = 583). Patients were treated
for 4 weeks with lumiracoxib (400 mg/day or 50,
100 or 200 mg bid), diclofenac (75 mg bid) or
placebo.
All regimens of lumiracoxib were
comparable to diclofenac and superior
to placebo in mean improvements in
VAS pain, WOMAC index, HAQ index
and global assessments.
454848
468864
Symptomatic relief of RA. Placebo-controlled phase II trials in RA patients
(n = 87 to 99 per arm) treated with lumiracoxib
(200 mg bid).
Lumiracoxib is comparable to
diclofenac in VAS pain over 24 h.
411639
Safety and tolerability. Phase I trial in healthy volunteers (n = 60)
treated with lumiracoxib (200 mg bid) or
naproxen (500 mg bid).
Duodenal erosions were detected in
13 of 20 subjects in the naproxen
group, whereas no erosions were
observed in the lumiracoxib group.
451842
Safety and tolerability. Phase I trial in healthy volunteers (n = 25)
treated with lumiracoxib (800 mg/day) or
naproxen (500 mg bid).
Ulcers or duodenal erosions were
detected in 75% of the naproxen group
and 12% of the placebo group; none
were detected in the lumiracoxib group.
451842
Pain relief. Phase II trial involving subjects with dental pain
(n = 202) treated with lumiracoxib (400 mg
single dose).
Lumiracoxib resulted in rapid and
prolonged pain relief and was superior
to ibuprofen and placebo in analgesic
onset.
448856
Symptomatic relief of OA. Placebo-controlled phase II trials in OA patients
(94 to 99 per arm) treated with lumiracoxib (400
mg/day).
Lumiracoxib shows significantly
greater pain relief compared to
placebo.
411639
Associated patent
Title Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives.
Assignee Novartis AG
Publication WO-09911605 11-MAR-99
Priority US-00069837 28-AUG-97
Inventors Fujimoto RA, McQuire LW, Mugrage BB, Van Duzer JH, Xu D.
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